Kyverna Therapeutics appoints Greg Martini as CFO
Source: SeekingAlpha
2026-05-18 08:16:02 ET
More on Kyverna Therapeutics
- Kyverna Therapeutics: 'Strong Buy' On Additional POC Of Miv-Cel In Myasthenia Gravis
- Kyverna Therapeutics Positive Phase 2 Readout: Deep Responses, But Very Small Sample
- Kyverna Therapeutics, Inc. (KYTX) Presents at Leerink Global Healthcare Conference 2026 Transcript
- Kyverna begins rolling BLA submission for miv-cel
- Kyverna rises on new mid-stage trial data for myasthenia gravis therapy
Read the full article on Seeking Alpha
For further details see:
Kyverna Therapeutics appoints Greg Martini as CFO
Kyverna Therapeutics Inc.
NASDAQ: KYTX
KYTX Trading
-2.78% G/L:
$7.68 Last:
212,187 Volume:
$7.96 Open:
KYTX Latest News
KYTX Stock Data
$448,450,247
32,219,865
0.32%
24
N/A
Biotechnology & Life Sciences
Healthcare
US
Emeryville
